Can a stronger eylea dose dry up wet AMD faster?
NCT ID NCT07434713
First seen Mar 11, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This study is testing how well a higher dose (8mg) of the drug Aflibercept, also known as Eylea, works in the first two months for people with wet age-related macular degeneration (AMD). Researchers will measure changes in retinal fluid and vision in 50 participants. The goal is to see if this stronger dose can quickly control the disease and reduce the need for frequent injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dept. of Ophthalmology, University Hospital, Inselspital
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aflibercept 8mg (Eylea) injection
What this could lead to
If successful, this could show that a higher dose of Aflibercept works quickly to dry up retinal fluid and improve vision in wet AMD patients.
What could go wrong
This is a small, early observational study with only 50 participants, so results may not apply to everyone. The higher dose may also carry increased risk of eye inflammation or other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.